Serological diagnosis of autoimmune bullous skin diseases: Prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Van Beek, Nina ^a   Rentzsch, Kristin ^b   Probst, Christian ^b   Komorowski, Lars ^b   Kasperkiewicz, Michael ^a   Fechner, Kai ^b   Bloecker, Inga M ^b   Zillikens, Detlef ^a   Stöcker, Winfried ^b   Schmidt, Enno ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Institute of Experimental Immunology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DESMOGLEIN 1; DESMOGLEIN 3;

ARTICLE; AUTOIMMUNE BULLOUS SKIN DISEASE; BIOCHIP; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CELL STRAIN HEK293; COMPARATIVE STUDY; ESOPHAGUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INCUBATION TIME; NONHUMAN; NUCLEOTIDE SEQUENCE; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIMATE; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

AUTOIMMUNE DISEASES; BASE SEQUENCE; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HEK293 CELLS; HUMANS; PROSPECTIVE STUDIES; SKIN DISEASES, VESICULOBULLOUS;

EID: 84864697562     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-49     Document Type: Article

References (63)

1. Autoimmune bullous disorders. Eming R, Hertl M, Clin Chem Lab Med 2006 44 144 149
2. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. Sardy M, Karpati S, Merkl B, Paulsson M, Smyth N, J Exp Med 2002 195 747 757
3. The diagnosis and treatment of autoimmune blistering skin diseases. Schmidt E, Zillikens D, Dtsch Arztebl Int 2011 108 399 405 I-III
4. Pemphigus in India. Kanwar AJ, De D, Indian J Dermatol Venereol Leprol 2011 77 439 449
5. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Marazza G, Pham HC, Scharer L, Pedrazzetti PP, Hunziker T, Trueb RM, Hohl D, Itin P, Lautenschlager S, Naldi L, Borradori L, Br J Dermatol 2009 161 861 868
6. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. Bertram F, Brocker EB, Zillikens D, Schmidt E, J Dtsch Dermatol Ges 2009 7 434 440
7. Prevalence and treatment of pemphigus in Iran. Chams-Davatchi C, Dermatol Clin 2011 29 681 683
8. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J, BMJ 2008 337 180
9. Incidence and Mortality of Bullous Pemphigoid in France. Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, Courville P, Bravard P, Remond B, Doffoel-Hantz V, Benichou J, J Invest Dermatol 2012 132 1998 2004
10. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. Jung M, Kippes W, Messer G, Zillikens D, Rzany B, J Am Acad Dermatol 1999 41 266 268
11. Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. Hahn-Ristic K, Rzany B, Amagai M, Brocker EB, Zillikens D, J Eur Acad Dermatol Venereol 2002 16 68 71
12. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Baican A, Baican C, Chiriac G, Chiriac MT, Macovei V, Zillikens D, Ciuce D, Sitaru C, Int J Dermatol 2010 49 768 774
13. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghohestani R, Hashimoto T, et al. Arch Dermatol 2002 138 370 379
14. Immunofluorescence in dermatology. Mutasim DF, Adams BB, J Am Acad Dermatol 2001 45 803 822
15. Modern diagnosis of autoimmune blistering skin diseases. Schmidt E, Zillikens D, Autoimmun Rev 2010 10 84 89
16. Role of immunofluorescence microscopy in dermatology. Pohla-Gubo G, Kraus L, Hintner H, G Ital Dermatol Venereol 2011 146 127 142
17. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S, Shimizu N, Nishikawa T, J Immunol 1997 159 2010 2017
18. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM, Br J Dermatol 2001 144 775 780
19. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. Yoshida M, Hamada T, Amagai M, Hashimoto K, Uehara R, Yamaguchi K, Imamura K, Okamoto E, Yasumoto S, Hashimoto T, J Dermatol Sci 2006 41 21 30
20. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Sitaru C, Dahnrich C, Probst C, Komorowski L, Blocker I, Schmidt E, Schlumberger W, Rose C, Stöcker W, Zillikens D, Exp Dermatol 2007 16 770 777
21. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Probst C, Schlumberger W, Stöcker W, Recke A, Schmidt E, Hashimoto T, Zhu XJ, Zillikens D, Komorowski L, Clin Chim Acta 2009 410 13 18
22. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Schmidt E, Dahnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stocker W, Hashimoto T, Brocker EB, et al. Exp Dermatol 2010 19 458 463
23. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. Saleh MA, Ishii K, Kim YJ, Murakami A, Ishii N, Hashimoto T, Schmidt E, Zillikens D, Shirakata Y, Hashimoto K, et al. J Dermatol Sci 2011 62 169 175
24. Substrate specificity of anti-epithelial antibodies of pemphigus vulgaris and pemphigus foliaceus sera in immunofluorescence tests on monkey and guinea pig esophagus sections. Sabolinski ML, Beutner EH, Krasny S, Kumar V, Huang J, Chorzelski TP, Sampaio S, Bystryn JC, J Invest Dermatol 1987 88 545 549
25. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, Briggaman RA, Beutner EH, J Am Acad Dermatol 1990 22 664 670
26. Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL, Arch Dermatol 1997 133 1102 1107
27. Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. Jiao D, Bystryn JC, J Am Acad Dermatol 1997 37 211 216
28. Rituximab in severe pemphigus. Schmidt E, Goebeler M, Zillikens D, Ann N Y Acad Sci 2009 1173 683 691
29. Pemphigoid gestationis: maternal sera recognize epitopes restricted to the N-terminal portion of the extracellular domain of BP180 not present on its shed ectodomain. Sitaru C, Powell J, Shimanovich I, Jainta S, Kirtschig G, Wojnarowska F, Zillikens D, Br J Dermatol 2003 149 420 422
30. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. Kobayashi M, Amagai M, Kuroda-Kinoshita K, Hashimoto T, Shirakata Y, Hashimoto K, Nishikawa T, J Dermatol Sci 2002 30 224 232
31. Development of an ELISA for the detection of autoantibodies to BP230. Kromminga A, Sitaru C, Hagel C, Herzog S, Zillikens D, Clin Immunol 2004 111 146 152
32. Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides. Kasperkiewicz M, Dahnrich C, Probst C, Komorowski L, Stocker W, Schlumberger W, Zillikens D, Rose C, J Am Acad Dermatol 2011 66 583 588
33. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Schmidt E, Skrobek C, Kromminga A, Hashimoto T, Messer G, Brocker EB, Yancey KB, Zillikens D, Br J Dermatol 2001 145 778 783
34. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. Zillikens D, Kawahara Y, Ishiko A, Shimizu H, Mayer J, Rank CV, Liu Z, Giudice GJ, Tran HH, Marinkovich MP, et al. J Invest Dermatol 1996 106 1333 1338
35. Comparative analysis of methods for detection of anti-laminin 5 autoantibodies in patients with anti-epiligrin cicatricial pemphigoid. Lazarova Z, Sitaru C, Zillikens D, Yancey KB, J Am Acad Dermatol 2004 51 886 892
36. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. Komorowski L, Müller R, Vorobyev A, Probst C, Recke A, Jonkman MF, Hashimoto T, Kim S-C, Groves R, Ludwig RJ, et al. J Am Acad Dermatol 2012 Epub ahead of print
37. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Groth S, Recke A, Vafia K, Ludwig RJ, Hashimoto T, Zillikens D, Schmidt E, Br J Dermatol 2011 164 76 82
38. Diagnosis and treatment of patients with autoimmune bullous disorders in Germany. Schmidt E, Zillikens D, Dermatol Clin 2011 29 663 671
39. A coefficient of agreement for nominal scales. Cohen J, Educational and Psychological Measurements 1960 20 37 46
40. The measurement of observer agreement for categorical data. Landis JR, Koch GG, Biometrics 1977 33 159 174
41. Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases. Csorba K, Schmidt S, Florea F, Ishii N, Hashimoto T, Hertl M, Karpati S, Bruckner-Tuderman L, Nishie W, Sitaru C, Orphanet J Rare Dis 2011 6 31
42. Anti-laminin gamma-1 pemphigoid. Dainichi T, Kurono S, Ohyama B, Ishii N, Sanzen N, Hayashi M, Shimono C, Taniguchi Y, Koga H, Karashima T, et al. PNAS 2008 106 2800 2805
43. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. Schepens I, Jaunin F, Begre N, Laderach U, Marcus K, Hashimoto T, Favre B, Borradori L, PLoS One 2010 5 12250
44. Place of human amniotic membrane immunoblotting in the diagnosis of autoimmune bullous dermatoses. Grootenboer-Mignot S, Descamps V, Picard-Dahan C, Nicaise-Roland P, Prost-Squarcioni C, Leroux-Villet C, Champagnat C, Delaval A, Aucouturier F, Crickx B, Chollet-Martin S, Br J Dermatol 2010 162 743 750
45. An extract of cultured A431 cells contains major tissue antigens of autoimmune bullous diseases. Lee CW, Br J Dermatol 2000 143 821 823
46. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, Izumi H, Ratrie H 3rd, Mutasim D, Ariss-Abdo L, et al. N Engl J Med 1990 323 1729 1735
47. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB, Lancet 2001 357 1850 1851
48. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Kirtschig G, Murrell D, Wojnarowska F, Khumalo N, Arch Dermatol 2002 138 380 384
49. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. Martin LK, Werth VP, Villaneuva EV, Murrell DF, J Am Acad Dermatol 2011 64 903 908
50. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. Joly P, Roujeau JC, Benichou J, Delaporte E, D'Incan M, Dreno B, Bedane C, Sparsa A, Gorin I, Picard C, et al. J Invest Dermatol 2009 129 1681 1687
51. Epitope mapping of BP230 leading to a novel enzyme-linked immunosorbent assay for autoantibodies in bullous pemphigoid. Blocker IM, Dahnrich C, Probst C, Komorowski L, Saschenbrecker S, Schlumberger W, Stocker W, Zillikens D, Schmidt E, Br J Dermatol 2012 166 964 970
52. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Charneux J, Lorin J, Vitry F, Antonicelli F, Reguiai Z, Barbe C, Tabary T, Grange F, Bernard P, Arch Dermatol 2011 147 286 291
53. A highly sensitive and simple assay for the detection of circulating autoantibodies against full-length bullous pemphigoid antigen 180. Schmidt E, Kromminga A, Mimietz S, Leinfelder U, Sitaru C, Brocker EB, Zillikens D, Zimmermann U, J Autoimmun 2002 18 299 309
54. Pathogenic anti-desmoglein MAbs show variable ELISA activity because of preferential binding of mature versus proprotein isoforms of desmoglein 3. Sharma PM, Choi EJ, Kuroda K, Hachiya T, Ishii K, Payne AS, J Invest Dermatol 2009 129 2309 2312
55. Pathogenic epitopes of autoantibodies in pemphigus reside in the amino-terminal adhesive region of desmogleins which are unmasked by proteolytic processing of prosequence. Yokouchi M, Saleh MA, Kuroda K, Hachiya T, Stanley JR, Amagai M, Ishii K, J Invest Dermatol 2009 129 2156 2166
56. Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180. Kromminga A, Scheckenbach C, Georgi M, Hagel C, Arndt R, Christophers E, Brocker EB, Zillikens D, J Autoimmun 2000 15 293 300
57. IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Christophoridis S, Budinger L, Borradori L, Hunziker T, Merk HF, Hertl M, Br J Dermatol 2000 143 349 355
58. The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy. Buijsrogge JJ, Diercks GF, Pas HH, Jonkman MF, Br J Dermatol 2011 165 92 98
59. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, Sebbag N, Pedicelli C, Sera F, Lacour JP, et al. Clin Immunol 2008 128 415 426
60. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Roussel A, Benichou J, Randriamanantany ZA, Gilbert D, Drenovska K, Houivet E, Tron F, Joly P, Arch Dermatol 2011 147 293 298
61. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Charneux J, Lorin J, Vitry F, Antonicelli F, Reguiai Z, Barbe C, Tabary T, Grange F, Bernard P, Arch Dermatol 2011 147 286 291
62. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Schmidt E, Obe K, Brocker EB, Zillikens D, Arch Dermatol 2000 136 174 178
63. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. Venning VA, Dermatol Clin 2011 29 453 458 ix